Metsera (MTSR) Collaboration summary
Event summary combining transcript, slides, and related documents.
Collaboration summary
20 Jan, 2026Opening remarks and agenda
Announcement of a collaboration to produce millions of pens and oral solids of GLP-1 products.
Emphasis on the uniqueness and excitement surrounding the partnership.
Objectives of the partnership
Aim to deliver high-quality, affordable GLP-1 medicines at scale.
Focus on healthy weight loss and empowering patients globally.
Partner introductions and roles
Amneal highlighted as a manufacturing powerhouse with over 280 prescription drugs and a strong quality track record.
Metsera brings expertise in molecule design and development.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Metsera
- Shareholders are asked to approve a merger with Pfizer, supported by major investors and the Board.MTSR
Proxy Filing2 Dec 2025 - Vote on merger with Pfizer: $47.50/share cash plus CVR; Board and key holders support approval.MTSRProxy Filing2 Dec 2025
- Shareholders must vote on Pfizer's contested acquisition amid litigation and competing bids.MTSRProxy Filing2 Dec 2025
- IPO targets $250.8M to fund late-stage obesity drug trials; high risk, high potential market.MTSRRegistration Filing29 Nov 2025
- IPO aims to fund late-stage obesity drug trials; lead asset shows promise but high risk remains.MTSRRegistration Filing29 Nov 2025
- Monthly and oral peptide assets advance rapidly, with major data readouts expected this year.MTSRBofA Securities 2025 Healthcare Conference17 Nov 2025
- Definitive merger with Pfizer at $65.60/share plus CVRs; Q3 net loss $116.2M, cash $448.5M.MTSRQ3 202512 Nov 2025
- Up to 8.4% weight loss achieved in five weeks with monthly dosing and mild, transient GI AEs.MTSRStudy Result12 Nov 2025
- Amended merger with Pfizer offers up to $86.25 per share; board unanimously recommends approval.MTSRProxy Filing10 Nov 2025